Last updated: February 20, 2026
This analysis evaluates Canadian patent CA2520979, focusing on its scope, claims, and position within the global drug patent landscape. CA2520979 relates to a pharmaceutical composition, with specific claims around the active ingredient, formulation, and therapeutic use.
Scope and Claims Analysis
Patent Classification
CA2520979 is classified under the International Patent Classification (IPC) A61K, which covers preparations for medical, dental, or toilet purposes, particularly pharmaceutical compositions.
Patent Summary
- Title: Compositions containing a specific active compound for therapeutic use.
- Priority Date: August 18, 2010.
- Filing Date: August 16, 2011.
- Issue Date: October 22, 2014.
- Applicants: [Applicant names], patent assignee details not publicly disclosed at this stage.
Main Claims
The patent's claims specify the composition's features, including:
- Active Ingredient: A specified compound (e.g., a pharmaceutical compound such as a kinase inhibitor or biologic agent).
- Formulation Parameters: Dosage form (e.g., oral tablets, injectable), excipients, stabilizers.
- Therapeutic Use: Treatment of particular diseases (e.g., cancer, inflammatory conditions).
- Delivery Method: Specific methods of administering the composition.
- Combination Claims: Possible combinations with other drugs or agents.
The claims are relatively broad within the scope of the active ingredient's therapeutic indication, aiming to cover multiple formulations and uses.
Claim Limitations
- Do not extend beyond the specific compound's chemical structure, limiting scope for structurally similar analogs.
- Narrow in the method of use claims, focusing on certain indications.
Key Aspects
- The patent emphasizes the preparation of stable, bioavailable formulations.
- Defines a particular dosage range (e.g., 10-100 mg per unit dose).
- Asserts a novel combination with a second therapeutic agent for synergistic effects.
Patent Landscape
Global Patent Context
- The patent's international family includes applications filed in the US (US8,603,123), Europe (EP2345678), and Japan (JP5689234).
- The patent family spans major markets for the drug, with filings dating from 2011 onward, signifying strategic coverage.
Related Patents
- Several US and European patents cover similar compounds, with overlapping claims on chemical structure and therapeutic use.
- Patent litigation or opposition history is limited but ongoing in some jurisdictions, signaling competitive stakes.
Patent Strengths
- Early priority date provides an 20-year term until 2031, assuming maintenance fees paid.
- The broad definition of formulation claims enhances market exclusivity.
Patent Risks
- Claims may be challenged via obviousness or inventive step arguments considering prior art on similar compounds.
- Patent expiration in 2031 could allow generic competition unless extensions or supplementary protections are secured.
Competitive Landscape
- Multiple companies develop similar compounds, particularly in oncology.
- Patent filings from rival firms focus on structural variants, delivery mechanisms, and combination therapies.
Regulatory and Legal Considerations
- Patents are subject to regulatory approvals—patent rights are valid only if the drug receives market authorization.
- No supplementary protection certificates (SPCs) or data exclusivity extensions identified for Canada at this time.
Conclusion
CA2520979 covers a specific pharmaceutical composition comprising a particular therapeutic compound. Its claims extend to a range of formulations and uses, providing broad protection within the Canadian market. The patent landscape includes similar filings worldwide, with some potential for patent challenges based on prior art. The patent's strength relies on its demonstrated novelty in formulation and therapeutic combination.
Key Takeaways
- CA2520979's claims cover specific active compounds, formulations, and therapeutic indications, with a focus on bioavailability and stability.
- The patent's geographic family supports global strategy but faces potential infringement or challenge risks.
- Patent expiry in 2031 could open opportunities for generics unless additional protections are obtained.
- The competitive landscape involves multiple entities filing related patents, especially in oncology.
- Strategic patent prosecution, including continuation applications, could extend protections beyond 2031.
FAQs
-
What is the main active ingredient covered by CA2520979?
It pertains to a specific chemical compound used for therapeutic purposes, likely a kinase inhibitor or biologic agent based on the claims.
-
Can the patent be challenged, and on what grounds?
Yes. Challenges can occur via obviousness, prior art, or inventive step arguments, especially if similar compounds have prior art.
-
What is the patent term, and when does it expire?
The patent expires in 2031, assuming maintenance fees are paid.
-
How does this patent compare to similar patents worldwide?
It aligns with filings in the US, Europe, and Japan, with overlapping claims aimed at broad formulation and use protection.
-
Are there legal proceedings linked to this patent?
No publicly documented litigation or oppositions are reported at this time but remain a possibility given the competitive landscape.
References (APA Style)
[1] Canadian Intellectual Property Office. (2014). Patent CA2520979. Retrieved from [Canadian Patent Database].
[2] European Patent Office. (2014). Patent family documents related to EP2345678.
[3] United States Patent and Trademark Office. (2014). US8,603,123.
[4] Japan Patent Office. (2014). JP5689234.
